Drugmakers in Australia call for Code of Conduct changes as more are fined
The on-going dispute in Australia over what constitutes a breach of the pharmaceutical industry's Code of Conduct for marketing and promotion of drugs has reached new heights with companies demanding changes to the code. The local subsidiaries of multinational drug majors Pfizer, Roche and Eli Lily and biotechnology firm Amgen are included in those calling for changes and clarifications as the sector industry group, Medicines Australia, reviews the code that applies to all companies supplying prescription medicines.
The Medicines Australia Code of Conduct has been in operation since the early 1960s, and the current 15th edition became effective in December 2006. The Code requires the trade body to carry out a review of its provisions, after seeking input from interested parties, no later than every three years. A review is now underway that will lead to the 16th edition.
23 firms fined A$1.83 million
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze